# OnCo record paper-checkmate-067-10-year-nejm-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-067-10-year-nejm-2025" ;
  schema:name "CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma"@en ;
  schema:description "Ten years after starting treatment, about half of patients with advanced melanoma treated with nivolumab plus ipilimumab were still alive, most without any further treatment, showing that immunotherapy can cure a disease that once killed most patients within a year."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2407417>, <https://clinicaltrials.gov/study/NCT01844505>, <https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025>, <https://doi.org/10.1056/NEJMoa1504030> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2407417> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al." ;
  onco:related <https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/>, <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/lag3/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:trials <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/relativity-047/> ;
  onco:people <https://onco.cc/people/john-haanen/>, <https://onco.cc/people/mcarthur-grant/>, <https://onco.cc/people/f-stephen-hodi/>, <https://onco.cc/people/james-larkin/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:journals <https://onco.cc/journals/nejm/> .
